Analysis Group Experts to Present HEOR and Epidemiology Research at AMCP Annual Meeting

April 17, 2026

Analysis Group’s HEOR, Epidemiology & Market Access practice presented 23 posters, including a gold ribbon awardee and a silver ribbon awardee, at the Academy of Managed Care Pharmacy’s (AMCP’s) annual meeting, which was held April 13–16, 2026, in Nashville, TN.

Gold Ribbon

  • Poster 366 – “Prediction of Overt Hepatic Encephalopathy using Machine Learning: a claims-based study of a prevalent cohort,” coauthored by an Analysis Group team – including Managing Principal Annie Guérin, Vice President Patrick S. Gagnon, Manager Thomas Cornwall, and Senior Research Professionals Nathan Gobeil and Kana Yokoji – in collaboration with researchers from Weill Cornell Medicine and Bausch Health (sponsor).

Silver Ribbon

  • Poster 356 – “Willingness to Trade Effectiveness for Other Contraceptive Features: A Discrete Choice Experiment,” coauthored by an Analysis Group team – including Managing Principal Keith A. Betts and Senior Analyst Lorraine Liu – in collaboration with The Ohio State University, University Hospitals, and Organon (sponsor).

Additional poster presentations include:

  • Poster 32 – “Risk of major atherosclerotic cardiovascular disease events in the United States among individuals with and without prior events,” coauthored by an Analysis Group team – including Vice President Yan Song and Manager Nicolae Done – in collaboration with researchers from Yale University, the University of Colorado, and Merck (sponsor).
  • Poster 37 – “Dose titration among patients receiving vericiguat in real-world clinical practice and association with clinical outcomes and health care resource use,” coauthored by an Analysis Group team – including Managing Principal James Signorovitch, Vice President Yan Song, Manager Nicolae Done, and Senior Analyst Ellen Sears – in collaboration with researchers from Kaiser Permanente, the Icahn School of Medicine at Mount Sinai, and Merck (sponsor).
  • Poster 39 – “Formulary Barriers to Accessing Finerenone for the Treatment of Chronic Kidney Disease (CKD) and Type 2 Diabetes (T2D),” coauthored by an Analysis Group team – including Managing Principal Keith A. Betts, Manager Aozhou Wu, and Associate Travis Wang – in collaboration with researchers from University of Utah and Bayer (sponsor).
  • Poster 67 – “Comparison of Amyloid-related Imaging Abnormalities Risk for Lecanemab versus Donanemab and the Potential Implications,” coauthored by an Analysis Group team – including Managing Principal Keith A. Betts and Associate Ariel Chao – in collaboration with researchers from Barrow Neurological Institute, Toronto Memory Program, and Yale School of Medicine.
  • Poster 107 – “Budget Impact of Introducing Tapinarof Cream 1% Once Daily, a New Aryl Hydrocarbon Receptor Agonist, for the Treatment of Atopic Dermatitis in Adult and Pediatric Patients, From a U.S. Commercial Plan Perspective,” coauthored by an Analysis Group team – including Manager David Proudman and Senior Analyst Avani Samandur – in collaboration with researchers from Schweiger Dermatology Group and Organon (sponsor).
  • Poster 122 – “Costs of first-line treatment of chronic lymphocytic leukemia/small lymphocytic lymphoma with Bruton tyrosine kinase inhibitors and simulation of the impact of the Inflation Reduction Act,” coauthored by an Analysis Group team – including Vice President Bruno Émond, Manager Jessica Maitland, Associate Elizabeth Hore, Senior Research Professional Gordon Wong, and Research Professional Shirley Zhu – in collaboration with researchers from AbbVie (sponsor).
  • Poster 246 – “Real-world use of xanomeline-trospium in schizophrenia: patient characteristics and antipsychotic treatment patterns,” coauthored by an Analysis Group team – including Principal François Laliberté, Manager Chi Gao - in collaboration with researchers from BMS (sponsor).
  • Poster 275 – “Budget impact analysis of revumenib for the treatment of relapsed or refractory (R/R) NPM1-mutated acute myeloid leukemia (AML) in the United States,” coauthored by an Analysis Group team – including Vice President Jenny Zhou, Manager Yanwen Xie, Associate Qianqian Gu, and Analyst Hekun Chen – in collaboration with researchers from the University of Arizona, HealthEcon Consulting, and Syndax Pharmaceuticals (sponsor).
  • Poster 277 – “The Economic Impact of Venetoclax plus Acalabrutinib Treatment Sequences for Chronic Lymphocytic Leukemia (CLL) in the United States (US): A Cost of Care and Budget Impact Model,” coauthored by an Analysis Group team – including Managing Principal Annie Guérin, Manager Nisha Hazra, and Senior Analyst Weiye Chen – in collaboration with researchers from the Stanford Cancer Institute, the Fred Hutchinson Cancer Research Center, the Dana Farber Cancer Institute, AbbVie (sponsor), and Genentech (sponsor).
  • Poster 283 – “Comparative economic analysis of B-cell maturation antigen (BCMA)-targeted bispecific antibodies (BsAbs) in triple-class exposed relapsed/refractory multiple myeloma (RRMM): linvoseltamab versus teclistamab and elranatamab,” coauthored by an Analysis Group team – including Vice President Jenny Zhou, Manager Nisha Hazra, Associate Michael Xu, Senior Analyst Jack Eales, and Analyst Hekun Chen – in collaboration with researchers from the Fred Hutchinson Cancer Center and Regeneron Pharmaceuticals (sponsor).
  • Poster 284 – “Budget Impact Analysis of Linvoseltamab for the Treatment of Relapsed/Refractory Multiple Myeloma (RRMM) in the United States,” coauthored by an Analysis Group team – including Vice President Jenny Zhou, Manager Nisha Hazra, Associate Michael Xu, Senior Analyst Jack Eales, and Analyst Hekun Chen – in collaboration with researchers from Regeneron Pharmaceuticals (sponsor).
  • Poster 292 – “Real-world treatment patterns, healthcare resource utilization, and costs among patients with unresectable/metastatic GEP-NETs after progression on somatostatin analogs-based therapy,” coauthored by an Analysis Group team – including Managing Principal Annie Guérin and Manager Jessica Maitland – in collaboration with researchers from Sanofi (sponsor).
  • Poster 296 – “Clinical and economic burden among patients with unresectable/metastatic GEP-NETs in second line or later following prior treatment with somatostatin analogs,” coauthored by an Analysis Group team – including Managing Principal Annie Guérin and Manager Jessica Maitland – in collaboration with researchers from the Winship Cancer Institute of Emory University and Sanofi (sponsor).
  • Poster 323– “Healthcare Resource Utilization With Cariprazine Versus Lumateperone Among Patients With Bipolar I Depression,” coauthored by an Analysis Group team – including Principal François Laliberté, Vice President Enrico Zanardo, Associate Susannah Ripley, and Senior Research Professional Sophie Ma – in collaboration with researchers from AbbVie (sponsor).
  • Poster 324 – “Real-World Disability Outcomes Among Patients Treated With Cariprazine Versus Quetiapine as Adjunctive Treatment for Major Depressive Disorder,” coauthored by an Analysis Group team – including Principal François Laliberté, Vice President Enrico Zanardo, and Associate Susannah Ripley– in collaboration with researchers from AbbVie (sponsor).
  • Poster 330 – “Persistence to Cariprazine Versus Other Atypical Antipsychotics in Real-World Treatment of Bipolar I Disorder and Adjunctive Treatment of Major Depressive Disorder,” coauthored by an Analysis Group team – including Principal François Laliberté, Vice President Enrico Zanardo, Associate Susannah Ripley, and Senior Research Professional Sophie Ma – in collaboration with researchers from AbbVie (sponsor).
  • Poster 337 – “Persistence of Cariprazine Vs Lumateperone Among Patients With Bipolar I Depression: A Real-World Claims-Based Study,” coauthored by an Analysis Group team – including Principal François Laliberté, Vice President Enrico Zanardo, Associate Susannah Ripley, and Senior Research Professional Sophie Ma – in collaboration with researchers from AbbVie (sponsor).
  • Poster 354 – “Contraception preferences of women and healthcare providers: A discrete choice experiment,” coauthored by an Analysis Group team – including Managing Principal Keith A. Betts and Senior Analyst Matthew Mattera – in collaboration with researchers from The Ohio State University, University Hospitals, and Organon (sponsor).
  • Poster 396 – “Medication access barriers for patients with idiopathic pulmonary fibrosis: A retrospective claims analysis,” coauthored by an Analysis Group team – including Vice President Dominic Pilon, Manager Carmine Rossi, Associate Frederic Kinkead, and Senior Research Professional Yuxi Wang – in collaboration with researchers from Baylor University Medical Center, Texas A&M University College of Medicine, and Boehringer Ingelheim (sponsor).
  • Poster 398 – “Using a claims-based algorithm to identify patients with refractory and unexplained chronic cough: navigating real-world claims database research without an International Classification of Diseases code,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Rose Chang, Manager Catherine Nguyen, Associate Adina Zhang, and Senior Analyst Leili Young-Xu – in collaboration with researchers from the University of California, Davis and GSK (sponsor).
  • Poster 402 – “Prevalence of refractory chronic cough and unexplained chronic cough in older adults (≥65 years) based on a claims algorithm using Optum Medicare Advantage prescription drug data,” coauthored by an Analysis Group team – including Managing Principal Mei Sheng Duh, Vice President Rose Chang, Manager Catherine Nguyen, Associate Adina Zhang, and Analyst Tingxi Long – in collaboration with researchers from the University of California, Davis and GSK (sponsor).